Application

SB 202190 was used to inhibit p38 activation in MCF7 cells⁵, mouse macrophages⁶ and HepG2 cells.⁷

Biochem/physiol Actions

SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase. SB 202190 binds within the ATP pocket of the active kinase (K_d = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

5, 25 mg in glass bottle